Porphyrin Cyclodextrin Conjugates Modulate Amyloid Beta Peptide Aggregation and Cytotoxicity

Area of Science:

• Biochemistry
• Neuroscience
• Materials Science

Background:

• Alzheimer's disease (AD) is characterized by amyloid beta peptide (Aβ) aggregates.
• Soluble Aβ oligomers, not just fibrils, are increasingly recognized as the primary toxic species in AD pathogenesis.
• Targeting these toxic oligomers presents a promising therapeutic avenue for AD.

Purpose of the Study:

• To investigate the biological properties of novel cyclodextrin-porphyrin derivatives and their zinc complex.
• To evaluate the potential of these compounds in interacting with Aβ and mitigating its cytotoxicity.
• To explore their efficacy in cellular models of amyloid aggregation.

Main Methods:

• Synthesis and characterization of 5[4-(6-O-β-cyclodextrin)-phenyl],10,15,20-tri(4-hydroxyphenyl)-porphyrin and its zinc complex.
• Cell-based assays to assess the interaction of the compounds with Aβ.
• Evaluation of the compounds' ability to cross cell membranes and promote intracellular Aβ clearance.
• Cytotoxicity assays to determine the protective effects against Aβ-induced toxicity.

Main Results:

• The synthesized cyclodextrin-porphyrin derivatives and their zinc complex effectively interact with Aβ.
• These molecules demonstrate the ability to permeate cell membranes.
• The compounds facilitate the intracellular delivery and subsequent clearance of Aβ.
• Significant reduction in Aβ-induced cytotoxicity was observed.

Conclusions:

• Cyclodextrin-porphyrin derivatives represent a novel class of molecules with the potential to target toxic Aβ oligomers.
• These compounds show promise as therapeutic agents for Alzheimer's disease by promoting Aβ clearance.
• Further development of these derivatives could lead to effective strategies for combating amyloid aggregation in neurodegenerative diseases.